20:00 , May 5, 2017 |  BC Week In Review  |  Clinical News

Cantex starts Ph II glioblastoma trial of CX-02

Cantex Pharmaceuticals Inc. (Weston, Fla.) began a Phase II trial of CX-02 to treat recurrent glioblastoma. The open-label, U.S. trial will evaluate objective response rate (ORR) as the primary endpoint in about 20 patients receiving...
07:00 , Jun 1, 2015 |  BC Week In Review  |  Clinical News

CX-01: Phase I data

An open-label, U.S. Phase I trial in 12 AML patients showed that induction chemotherapy consisting of cytarabine and idarubicin plus CX-01 as a continuous infusion for 7 days following a bolus led to morphologic complete...
07:00 , Oct 4, 2010 |  BC Week In Review  |  Company News

Tigris Pharmaceuticals board of directors update

Tigris Pharmaceuticals Inc. , Bonita Springs, Fla.   Business: Cancer   Appointed: Neil Flanzraich, chairman of ParinGenix Inc. , as executive chairman  ...
07:00 , Jul 6, 2009 |  BC Week In Review  |  Company News

Ligand, ParinGenix deal

ParinGenix received exclusive rights to three of Ligand's U.S. patents covering desulfated heparin compounds for the potential treatment of chronic obstructive pulmonary disease (COPD) and other indications. Ligand will receive $350,000 up front and is...
07:00 , Aug 1, 2005 |  BC Week In Review  |  Company News

ParinGenix management update

ParinGenix Inc. , Tucson, Ariz.   Business: Cardiovascular   Hired: Eric Leire as CEO, formerly president and CEO at APT Therapeutics Inc.  ...
08:00 , Feb 14, 2005 |  BC Week In Review  |  Clinical News

PGX-100: Start Phase I

ParinGenix will begin this month a placebo-controlled, dose-escalation, U.S. Phase I trial. ParinGenix Inc. , Tucson, Ariz.   Product: PGX-100   Business: Cardiovascular   Molecular target: Elastase ; Cathepsin G   Description: Heparin derivative, 2-O,...